Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma

References

• Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):1–10. doi:10.1007/s00401-016-1545-1.
   PubMed Web of Science ®Google Scholar
• Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol. 2000;1:459–468.
   PubMedGoogle Scholar
• Buckner JC, Brown PD, O‘Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. Mayo Clin Proc. 2007;82(10):1271–1286. doi:10.4065/82.10.1271.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, van Den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. doi:10.1016/s1470-2045(09)70025-7.
   PubMed Web of Science ®Google Scholar
• Rape A, Ananthanarayanan B, Kumar S. Engineering strategies to mimic the glioblastoma microenvironment. Adv Drug Deliv Rev. 2014;79-80:172–183. doi:10.1016/j.addr.2014.08.012.
   PubMed Web of Science ®Google Scholar
• Nusblat LM, Carroll MJ, Roth CM. Crosstalk between M2 macrophages and glioma stem cells. Cell Oncol (Dordr). 2017;40(5):471–482. doi:10.1007/s13402-017-0337-5.
   PubMed Web of Science ®Google Scholar
• Shi Y, Ping YF, Zhou W, He ZC, Chen C, Bs B, Zhang L, Chen L, Lan X, Zhang XC, et al. Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth. Nat Commun. 2017;8:15080. doi:10.1038/ncomms15080.
   PubMed Web of Science ®Google Scholar
• Graeber MB, Scheithauer BW, Kreutzberg GW. Microglia in brain tumors. Glia. 2002;40(2):252–259. doi:10.1002/glia.10147.
   PubMed Web of Science ®Google Scholar
• Garris C, Pittet MJ. Therapeutically reeducating macrophages to treat GBM. Nat Med. 2013;19(10):1207–1208. doi:10.1038/nm.3355.
   PubMed Web of Science ®Google Scholar
• Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10(1). 58. doi:10.1186/s13045-017-0430-2.
   PubMed Web of Science ®Google Scholar
• Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence T, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14–20. doi:10.1016/j.immuni.2014.06.008.
   PubMed Web of Science ®Google Scholar
• Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol. 2016;17(1):34–40. doi:10.1038/ni.3324.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025.
   PubMed Web of Science ®Google Scholar
• Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, et al. Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013;15(8):1079–1087. doi:10.1093/neuonc/not082.
   PubMed Web of Science ®Google Scholar
• Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT, Cotzia P, Hooper DC. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res. 2013;19(14):3776–3786. doi:10.1158/1078-0432.CCR-12-1940.
   PubMed Web of Science ®Google Scholar
• Zwadlo G, Voegeli R, Schulze Osthoff K, Sorg C. A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol. 1987;55:295–304.
   PubMedGoogle Scholar
• Law SK, Micklem KJ, Shaw JM, Zhang XP, Dong Y, Willis AC, Mason DY. A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily. Eur J Immunol. 1993;23(9):2320–2325. doi:10.1002/eji.1830230940.
   PubMed Web of Science ®Google Scholar
• Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature. 2001;409(6817):198–201. doi:10.1038/35051594.
   PubMed Web of Science ®Google Scholar
• Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol. 2007;178:8183–8194.
   PubMed Web of Science ®Google Scholar
• Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, Richardson BC. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol. 2002;169:6020–6029.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 2001;15:837–846.
   PubMed Web of Science ®Google Scholar
• Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, Paramo JA, Ortega L, Egido J, Blanco-Colio LM. The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis. 2009;207(1):103–110. doi:10.1016/j.atherosclerosis.2009.04.033.
   PubMed Web of Science ®Google Scholar
• Fabriek BO, van Bruggen R, Deng DM, Ligtenberg AJ, Nazmi K, Schornagel K, Vloet RP, Dijkstra CD, van Den Berg TK. The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood. 2009;113(4):887–892. doi:10.1182/blood-2008-07-167064.
   PubMed Web of Science ®Google Scholar
• Backe E, Schwarting R, Gerdes J, Ernst M, Stein H. Ber-MAC3: new monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol. 1991;44:936–945.
   PubMed Web of Science ®Google Scholar
• Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010;47(7–8):1650–1660. doi:10.1016/j.molimm.2010.02.008.
   PubMed Web of Science ®Google Scholar
• Franco R, Fernandez-Suarez D. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol. 2015;131:65–86. doi:10.1016/j.pneurobio.2015.05.003.
   PubMed Web of Science ®Google Scholar
• Colin S, Chinetti-Gbaguidi G, Staels B. Macrophage phenotypes in atherosclerosis. Immunol Rev. 2014;262(1):153–166. doi:10.1111/imr.12218.
   PubMed Web of Science ®Google Scholar
• Lisi L, Ciotti GM, Braun D, Kalinin S, Curro D, Dello Russo C, Coli A, Mangiola A, Anile C, Feinstein DL, et al. Expression of iNOS, CD163 and ARG-1 taken as M1 and M2 markers of microglial polarization in human glioblastoma and the surrounding normal parenchyma. Neurosci Lett. 2017;645:106–112. doi:10.1016/j.neulet.2017.02.076.
   PubMed Web of Science ®Google Scholar
• Graversen JH, Svendsen P, Dagnaes-Hansen F, Dal J, Anton G, Etzerodt A, Petersen MD, Christensen PA, Moller HJ, Moestrup SK. Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol Ther. 2012;20(8):1550–1558. doi:10.1038/mt.2012.103.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Hirahara J, Horikawa T, Kawamura K, Kiyota E, Sakashita N, Araki N, Takeya M. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J histochem cytochem. 2006;54(7):763–771. doi:10.1369/jhc.5A6871.2006.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612.
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautes-Fridman C, Fridman WH, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218. doi:10.1186/s13059-016-1070-5.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205.
   PubMed Web of Science ®Google Scholar
• Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56:4625–4629.
   PubMed Web of Science ®Google Scholar
• Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618–631. doi:10.1038/nrc2444.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Zhang D, Gong B, Wang P, Liu F. CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer. Oncotarget. 2017;8(50):87244–87262. doi:10.18632/oncotarget.20244.
   PubMedGoogle Scholar
• Zhou J, Wang XH, Zhao YX, Chen C, Xu XY, Sun Q, Wu HY, Chen M, Sang JF, Su L, et al. Cancer-associated fibroblasts correlate with tumor-associated macrophages infiltration and lymphatic metastasis in triple negative breast cancer patients. J Cancer. 2018;9(24):4635–4641. doi:10.7150/jca.28583.
   PubMed Web of Science ®Google Scholar
• Zhang A, Qian Y, Ye Z, Chen H, Xie H, Zhou L, Shen Y, Zheng S. Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. Cancer Med. 2017;6(2):463–470. doi:10.1002/cam4.993.
   PubMed Web of Science ®Google Scholar
• Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009;11(2):R15. doi:10.1186/bcr2234.
   PubMed Web of Science ®Google Scholar
• Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schworer AM, Wagner U, Muller-Brusselbach S, et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134(1):32–42. doi:10.1002/ijc.28335.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Ohnishi K, Kuratsu J, Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008;216(1):15–24. doi:10.1002/path.2370.
   PubMed Web of Science ®Google Scholar
• Yang MY, Zetler PM, Prins RM, Khan-Farooqi H, Liau LM. Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications. Expert Rev Neurother. 2006;6(10):1481–1494. doi:10.1586/14737175.6.10.1481.
   PubMedGoogle Scholar
• Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev. 2008;222:70–100. doi:10.1111/j.1600-065X.2008.00603.x.
   PubMed Web of Science ®Google Scholar
• Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC. Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol. 2005;23(5):953–964. doi:10.1200/JCO.2005.12.172.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51. doi:10.1016/j.cell.2010.03.014.
   PubMed Web of Science ®Google Scholar
• Koh YW, Park CS, Yoon DH, Suh C, Huh J. CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma. PLoS One. 2014;9(1):e87066. doi:10.1371/journal.pone.0087066.
   PubMed Web of Science ®Google Scholar
• Han Q, Shi H, Liu F. CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol. 2016;34:101–106. doi:10.1016/j.intimp.2016.01.023.
   PubMed Web of Science ®Google Scholar
• Kubota K, Moriyama M, Furukawa S, Rafiul H, Maruse Y, Jinno T, Tanaka A, Ohta M, Ishiguro N, Yamauchi M, et al. CD163(+)CD204(+) tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma. Sci Rep. 2017;7(1):1755. doi:10.1038/s41598-017-01661-z.
   PubMed Web of Science ®Google Scholar
• Wang F, Yang L, Gao Q, Huang L, Wang L, Wang J, Wang S, Zhang B, Zhang Y. CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion. Cancer Immunol Immunother. 2015;64(8):965–976. doi:10.1007/s00262-015-1701-9.
   PubMed Web of Science ®Google Scholar
• Yang L, Wang F, Wang L, Huang L, Wang J, Zhang B, Zhang Y. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients. Oncotarget. 2015;6(12):10592–10603. doi:10.18632/oncotarget.3547.
   PubMedGoogle Scholar
• Zhu C, Kros JM, Cheng C, Mustafa D. The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies. Neuro Oncol. 2017;19(11):1435–1446. doi:10.1093/neuonc/nox081.
   PubMed Web of Science ®Google Scholar
• Lu W, Su L, Yu Z, Zhang S, Miao J. The new role of CD163 in the differentiation of bone marrow stromal cells into vascular endothelial-like cells. Stem Cells Int. 2016; 2016:2539781.doi:10.1155/2016/2539781.
   PubMed Web of Science ®Google Scholar
• Fabriek BO, Van Haastert ES, Galea I, Polfliet MM, Dopp ED, Van Den Heuvel MM, Van Den Berg TK, De Groot CJ, Van Der Valk P, Dijkstra CD. CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. Glia. 2005;51(4):297–305. doi:10.1002/glia.20208.
   PubMed Web of Science ®Google Scholar
• Wenzel I, Roth J, Sorg C. Identification of a novel surface molecule, RM3/1, that contributes to the adhesion of glucocorticoid-induced human monocytes to endothelial cells. Eur J Immunol. 1996;26(11):2758–2763. doi:10.1002/eji.1830261131.
   PubMed Web of Science ®Google Scholar
• Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196(3):254–265. doi:10.1002/path.1027.
   PubMed Web of Science ®Google Scholar
• Marchesi F, Cirillo M, Bianchi A, Gately M, Olimpieri OM, Cerchiara E, Renzi D, Micera A, Balzamino BO, Bonini S, et al. High density of CD68+/CD163+ tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma. Hematol Oncol. 2015;33(2):110–112. doi:10.1002/hon.2142.
   PubMed Web of Science ®Google Scholar
• Maxwell R, Jackson CM, Lim M. Clinical trials investigating immune checkpoint blockade in glioblastoma. Curr Treat Options Oncol. 2017;18(8):51. doi:10.1007/s11864-017-0492-y.
   PubMed Web of Science ®Google Scholar
• Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846–859. doi:10.1016/j.ccr.2014.05.016.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057–5069. doi:10.1158/0008-5472.can-13-3723.
   PubMed Web of Science ®Google Scholar
• Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, et al. CSF1R(+) macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Rep. 2018;23(5):1448–1460. doi:10.1016/j.celrep.2018.03.131.
   PubMed Web of Science ®Google Scholar
• Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guerin M, Biton J, Ouakrim H, et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A. 2018;115(17):E4041–e4050. doi:10.1073/pnas.1720948115.
   PubMed Web of Science ®Google Scholar
• Eissler N, Mao Y, Brodin D, Reutersward P, Andersson Svahn H, Johnsen JI, Kiessling R, Kogner P. Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. Oncoimmunology. 2016;5(12):e1232222. doi:10.1080/2162402x.2016.1232222.
   PubMed Web of Science ®Google Scholar
• Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Can. 2017;5(1):53. doi:10.1186/s40425-017-0257-y.
   PubMed Web of Science ®Google Scholar
• Greisen SR, Moller HJ, Stengaard-Pedersen K, Hetland ML, Horslev-Petersen K, Jorgensen A, Hvid M, Deleuran B. Soluble macrophage-derived CD163 is a marker of disease activity and progression in early rheumatoid arthritis. Clin Exp Rheumatol. 2011;29:689–692.
   PubMed Web of Science ®Google Scholar